Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe amplification

British Journal of Cancer

Volumn 91, Issue 6, 2004, Pages 1155-1159

  Bunyan, D J ^a   Eccles, D M ^b   Sillibourne, J ^a   Wilkins, E ^a   Thomas, Simon J ^a   Shea Simonds, J ^b   Duncan, P J ^a   Curtis, C E ^a   Robinson, D O ^a   Harvey, J F ^a   Cross, N C P ^a  

^a SALISBURY DISTRICT HOSPITAL   (United Kingdom)

^b PRINCESS ANNE HOSPITAL   (United Kingdom)

Author keywords

APC; BRCA1; BRCA2; hMLH1; hMSH2; MLPA

Indexed keywords

APC PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; DNA;

ARTICLE; BREAST CANCER; CANCER SCREENING; CANCER SUSCEPTIBILITY; COHORT ANALYSIS; COLORECTAL CANCER; FAMILIAL CANCER; GENE; GENE AMPLIFICATION; GENE DOSAGE; GENE MUTATION; HEALTH CARE COST; HMLH1 GENE; HMSH2 GENE; HUMAN; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; NUCLEOTIDE SEQUENCE; ONCOGENE; OVARY CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ADENOMATOUS POLYPOSIS COLI; BREAST NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; NEOPLASMS; OVARIAN NEOPLASMS;

EID: 5044227573     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602121     Document Type: Article

References (14)

1. Charbonnier F, Olschwang S, Wang Q, Boisson C, Martin C, Buisine MP, Puisieux A, Frebourg T (2002) MSH2 in contrast to MLH1 and MSH6 is frequently inactivated by exonic and promoter rearrangements in hereditary nonpolyposis colorectal cancer. Cancer Res 62: 848-853
2. Di Fiore F, Charbonnier F, Martin C, Frerot S, Olschwang S, Wang Q, Boisson C, Buisine M-P, Nilbert M, Lindblom A, Frebourg T (2004) Screening for genomic rearrangements of the MMR genes must be included in the routine diagnosis of HNPCC. J Med Genet 41: 18-20
3. Evans G, Eccles DM, Rahman N, Young K, Bulman M, Amir E, Shenton A, Howell A, Lalloo F (2004) A new scoring system for the chances of identifying a BRCA1/2 mutation, outperforms existing models including BRCAPRO. J Med Genet 41: 474-480
4. Gille JJ, Hogervorst FB, Pals G, Wijnen JT, van Schooten RJ, Dommering CJ, Meijer GA, Craanen ME, Nederlof PM, de Jong D, McElgunn CJ, Schouten JP, Menko FH (2002) Genomic deletions of MSH2 and MLH1 in colorectal cancer families detected by a novel mutation detection approach. Br J Cancer 87: 892-897
5. Hogervorst FB, Nederlof PM, Gille JJ, McElgunn CJ, Grippeling M, Pruntel R, Regnerus R, van Welsem T, van Spaendonk R, Menko FH, Klujit I, Dommering C, Verhoef S, Schouten JP, van't Veer LJ, Pals G (2003) Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. Cancer Res 63: 1449-1453
6. Montagna M, Palma MD, Menin C, Agata S, De Nicolo A, Chieco-Bianchi L, D'Andrea E (2003) Genomic rearrangements account for more than one-third of the BRCA1 mutations in northern Italian breast/ovarian cancer families. Hum Mol Genet 12: 1055-1061
7. Nakagawa H, Hampel H, de la Chapelle A (2003) Identification and characterisation of genomic rearrangements of MSH2 and MLH1 in Lynch syndrome (HNPCC) by novel techniques. Hum Mutat 22: 258
8. Petrij-Bosch A, Peelen T, van Vliet M, van Eijk R, Olmer R, Drusedau M, Hogervorst FB, Hageman S, Arts PJ, Ligtenberg MJ, Meijers-Heijboer H, Klijn JG, Vasen HF, Cornelisse CJ, van't Veer LJ, Bakker E, van Ommen GJ, Devilee P (1997) BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet 17: 341-345
9. Plummer SJ, Anton-Culver H, Webster L, Noble B, Liao S, Kennedy A, Belinson J, Casey G (1995) Detection of BRCA1 mutations by the protein truncation test. Hum Mol Genet 4: 1989-1991
10. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G (2002) Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependant probe amplification. Nucleic Acid Res 30: e57
11. Sieber OM, Lamlum H, Crabtree MD, Rowan AJ, Barclay E, Lipton L, Hodgson S, Thomas HJ, Neale K, Phillips RK, Farrington SM, Dunlop MG, Mueller HJ, Bisgaard ML, Bulow S, Fidalgo P, Albuquerque C, Scarano MI, Bodmer W, Tomlinson IP, Heinimann K (2002) Whole-gene APC deletions cause classical familial adenomatous polyposis, but not attenuated polyposis or 'multiple' colorectal adenomas. Proc Natl Acad Sci USA 99: 2954-2958
12. Taylor F, Charlton RS, Burn J, Sheridan E, Taylor GR (2003) Genomic deletions in MSH2 or MLH1 are a frequent cause of hereditary nonpolyposis colorectal cancer: identification of novel and recurrent deletions by MLPA. Hum Mutat 22: 428-433
13. Wagner A, Barrows A, Wijnen JT, van der Klift H, Franken PF, Verkuijlen P, Nakagawa H, Geugien M, Jaghmohan-Changur S, Breukel C, Meijers-Heijboer H, Morreau H, van Puijenbroek M, Burn J, Coronel S, Kinarski Y, Okimoto R, Watson P, Lynch JF, de la Chapelle A, Lynch HT, Fodde R (2003) Molecular analysis of hereditary nonpolyposis colorectal cancer in the United States: high mutation detection rate among clinically selected families and characterisation of an American founder genomic deletion of the MSH2 gene. Am J Hum Genet 72: 1088-1100
14. Wang Y, Friedl W, Lamberti C, Jungck M, Mathiak M, Pagenstecher C, Propping P, Mangold E (2003) Hereditary nonpolyposis colorectal cancer: frequent occurrence of large genomic deletions in MSH2 and MLH1 genes. Int J Cancer 103: 636-641